Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Atara Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Atara Biotherapeutics, Inc.

ATRA

Atara Biotherapeutics, Inc.

About Atara Biotherapeutics, Inc.

Atara Biotherapeutics develops allogeneic T-cell immunotherapies targeting Epstein-Barr virus (EBV)-associated diseases, primarily focusing on its approved product Ebvallo (tab-cel) for EBV-positive post-transplant lymphoproliferative disease (PTLD). Leveraging a proprietary EBV T-cell platform, Atara creates off-the-shelf treatments designed for rapid delivery to immunocompromised patients. The company partners with Pierre Fabre for commercialization in Europe and select global markets, operating through licensing, manufacturing, and royalty-based revenue models.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Atara Biotherapeutics, Inc.

1
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports Significant Revenue Decline and Net Loss in Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports $32.7 Million Net Income for 2025, Significant Turnaround from Previous Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports Significant Revenue Decline and Workforce Reductions in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports $40.4M Net Income for First Half of 2025, Faces Liquidity Concerns

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports $38M Net Income Turnaround, Driven by Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports $85.4M Net Loss and $128.9M Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Atara Biotherapeutics, Inc. Atara Biotherapeutics Reports Significant Revenue Growth, Net Loss Reduction in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments